ANDA 220675, held by Ascent Pharms Inc. Guanfacine Hydrochloride.
As of Nov 16, 2026, ANDA 220675 (Guanfacine Hydrochloride), held by Ascent Pharms Inc, was first approved by FDA on Mar 24, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 24, 2026 | Original application | Approved | None posted |
| Guanfacine HydrochlorideEQ 1MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
| Guanfacine HydrochlorideEQ 2MG BASE · tablet;oral | Guanfacine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters